Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
67
resultados
Última actualización
05/04/2026 [07:55:00]
Resultados 25 a 50 de 67
Resumen de: AU2024325238A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: AU2024345495A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: US20260061081A1
The present disclosure describes formulations, methods, and devices tor biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
Resumen de: AU2024277300A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: CN121577904A
本申请公开了一种检测阿尔兹海默病的试纸条及其应用，该试纸条采用胶体金‑辣根过氧化物酶复合物标记技术，通过酶信号放大显著提高了检测灵敏度，可同步检测血液中的两种关键AD生物标志物：p‑Tau‑181和Aβ1‑42。试纸条包括样品垫、标记垫、硝酸纤维素膜及吸水纸，硝酸纤维素膜上设有分别捕获p‑Tau‑181和Aβ1‑42的两条检测线（T1、T2）及一条质控线（C）。具有高灵敏度、快速检测、操作简便、成本低廉，适用于基层医疗和大规模筛查场景，对阿尔兹海默病早期诊断和普及防控具有重要价值。
Resumen de: CN121577908A
本发明公开了一种用于检测汗液中HCG蛋白的复合材料及其制备方法和在AD诊断中的应用，属于生物传感技术领域。该复合材料包括碳纳米管与1T相二硫化钼构成的复合基底材料，以及通过交联剂固定在该基底上的、能够特异性结合HCG蛋白的多肽分子。其制备方法包括采用一锅法溶剂热反应合成CNTs/1T‑MoS₂复合基底，对其进行羧基化修饰，然后与多肽分子偶联。本发明还将该材料固定于工作电极表面，制成传感器，并可集成于微流控芯片形成可穿戴检测贴片。该复合材料与传感器对AD汗液标志物HCG蛋白具有超高灵敏度（检测限达0.45 pg/mL）和特异性，实现了AD的无创、便捷早期诊断，显著提高了患者接受度。
Resumen de: JP2025137567A
To provide phospho-tau antibodies, and to provide methods of use thereof.SOLUTION: Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays. Provided herein is a method for detecting phosphorylated tau in a sample from an individual comprising: performing an immunoassay on the sample using an antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), the VH comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 30 to 34, and the VL comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 35 to 40.SELECTED DRAWING: None
Resumen de: WO2026044051A1
CD9 expressing microglia are observed in various human neurodegenerative diseases beyond traumatic brain injuries, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CD9 blocking and FcγRIII blocking methods can be widely used as an intervention strategy to prevent disease-associated cognitive impairment. Therefore, disclosed herein are methods for treating a traumatic brain injury in a subject in need thereof that involve the step of administering to the subject a therapeutically effective amount of a composition comprising an anti-CD9 or an anti FcγRIII blocking agent, such as a blocking antibody.
Resumen de: WO2026044151A1
Provided are recombinant diagnostic and therapeutic molecules and methods for their use in detecting and targeting Bcl-2 family proteins and/or Bcl-2 binding partners that are expressed on the surface of a cell or extracellular vesicle (EV) associated with the cancer, disease, or other condition.
Resumen de: WO2026044141A1
Provided are recombinant diagnostic and therapeutic molecules and methods for their use in detecting and targeting Bcl-2 family proteins and/or Bcl-2 binding partners that are expressed on the surface of a cell or extracellular vesicle (EV) associated with the cancer, disease, or other condition.
Resumen de: WO2024220662A2
This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Resumen de: CN121559077A
本发明公开了基于荧光探针的ATP水解酶抗体高效筛选法，包括生化体系和细胞体系两种检测方案，在生化体系中，通过定量ENTPD2蛋白水解ATP后剩余量，直接计算抗体抑制率；在细胞体系中，利用过表达ENTPD2的细胞验证抗体对跨膜酶的抑制功能。该生化体系方法无需抗体纯化，仅需5-15μL B细胞上清液即可完成初筛，筛选准确度高(细胞体系可用作验证筛选得到的抗体)，与体内药效结果一致，适用于抗ENTPD2抗体药物的开发，显著降低研发成本。
Resumen de: CN121554563A
本发明公开了一种蛋白连接酶介导的特异性修饰多肽的合成方法，属于生物工程技术领域。本发明解决了现有技术中磷酸化Tau蛋白难以大规模生产的问题，通过使用Tau多肽来替代全长位点特异性磷酸化Tau蛋白用作临床诊断试剂盒中阳性标品，利用蛋白连接酶催化，实现分段合成含有磷酸化特异性修饰多肽，可将不同来源的多肽在温和条件下高效、定向地连接起来，从而获得结构完整、功能多样的目标蛋白或多肽分子，有效提高肽键合成生产效率。
Resumen de: CN121559086A
本发明属于分子检测技术领域，提供一种双重检测NFL和NFH蛋白的单分子免疫法试剂盒。本发明提供的试剂盒包括固定特异性捕获抗体的固相载体、识别不同表位且标记可区分信号标记物的检测抗体，及洗涤液、封闭液、校准品、质控品，通过夹心免疫反应结合单分子检测技术，能够同步检测样品中NFL和NFH的含量。本发明提供的试剂盒，检测灵敏度可达fg/mL级别，且特异性强、操作简便，无需创伤性脑脊液采集，适用于神经退行性疾病的早期诊断、病情监测及疗效评估。
Resumen de: KR20260024607A
본 발명은 아밀로이드 베타(amyloid beta, Aβ)와 특이적으로 결합하는 클러스터린(clusterin) 펩타이드 및 이의 용도에 관한 것이다. 본 발명의 아밀로이드 베타(Aβ)의 특이적으로 결합하는 클러스터린 유래 폴리펩타이드를 이용하는 경우, 아밀로이드 베타의 섬유화 및 올리고머화를 방지할 수 있으므로, 아밀로이드 베타 관련 퇴행성 신경질환의 치료 및 예방에 사용할 수 있으며, 뿐만 아니라, 클러스터린 베타 서브유닛(clusterin-β subunit)은 아밀로이드 베타 관련 퇴행성 신경질환의 진단을 위한 바이오마커로서 활용될 수 있다.
Resumen de: US20260048083A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Resumen de: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
Resumen de: AU2026200694A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies. an a n
Resumen de: WO2026039416A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: EP4697021A2
An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.
Resumen de: CN121540882A
本发明公开了磷酸化Tau蛋白和磁珠的偶联物及其制备方法和试剂盒，涉及免疫分析技术领域。本申请通过将修饰有叠氮基团的改性磁珠和修饰有DBCO基团的改性抗磷酸化Tau蛋白的抗体通过点击化学的方式高效、定向偶联，相比传统物理吸附或非特异性化学偶联方法，具有偶联效率高、结合稳定性强、抗体活性保留率高等优势，可显著提升磁珠对血液中低丰度p‑Tau的捕获效率和特异性，检测下限低至0.3 pg/mL以下，在早期AD的诊断中展现出卓越的准确性，能够精准识别早期AD患者血液中p‑Tau的细微变化，为AD的早期筛查、病程监测及干预效果评估提供了可靠的工具。
Resumen de: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Nº publicación: CN121522171A 13/02/2026
Solicitante:
安徽梅赛泰生物科技有限公司
Resumen de: CN121522171A
本发明公开了一种多重级联放大的超灵敏化学发光试剂盒及其应用，属于试剂盒技术领域，该试剂盒包括链霉亲和素包被的磁性微粒试剂、生物素‑链霉亲和素桥接复合物试剂和吖啶酯标记的检测抗体试剂；链霉亲和素包被的磁性微粒试剂是以超顺磁微粒为起始物，以生物素衍生物为桥联剂，通过生物素衍生物与链霉亲和素交替、逐层偶联制备而成，其最外层为链霉亲和素；生物素‑链霉亲和素桥接复合物试剂是捕获抗体为起始物，以链霉亲和素为桥联剂，通过链霉亲和素和生物素衍生物交替、逐层偶联制备而成，其最外层为生物素衍生物，本发明试剂盒适用于如阿尔茨海默病早期诊断或细胞因子风暴等低丰度疾病标志物的体外检测。
BOPI
Sede Electrónica
